- Home
- AES vs LEGN Comparison
AES vs LEGN Comparison
Compare AES & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AES | LEGN |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 5.9B |
| IPO Year | 1991 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AES | LEGN |
|---|---|---|
| Price | $13.84 | $22.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $15.70 | ★ $69.67 |
| AVG Volume (30 Days) | ★ 7.0M | 2.5M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | ★ 5.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $12,094,000,000.00 | $909,045,000.00 |
| Revenue This Year | $1.13 | $68.83 |
| Revenue Next Year | $4.33 | $51.27 |
| P/E Ratio | $9.45 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $9.46 | $22.28 |
| 52 Week High | $15.51 | $45.30 |
Technical Indicators
Market Signals| Indicator | AES | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 21.96 |
| Support Level | $13.66 | $26.43 |
| Resistance Level | $14.20 | $28.97 |
| Average True Range (ATR) | 0.29 | 1.57 |
| MACD | 0.01 | -0.43 |
| Stochastic Oscillator | 29.36 | 0.91 |
Price Performance
Historical ComparisonAbout AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.